BioSquare

BioSquare is a South Korean biotechnology company focused on developing high-sensitivity diagnostic solutions using proprietary Quantum Dot (QD) technology. By leveraging the unique optical properties of quantum dots, the company's platform enhances the detection limits of lateral flow immunoassays, providing laboratory-grade accuracy in a rapid point-of-care format. BioSquare's commercial portfolio includes diagnostic kits for respiratory infections like COVID-19 and Influenza, supported by dedicated fluorescence readers for quantitative results. The company aims to expand its technology into cardiac markers, hormones, and other critical diagnostic fields to improve global healthcare access. Founded in 2017, BioSquare bridges the gap between traditional rapid tests and complex molecular diagnostics.